Prestige Consumer Healthcare Inc. (NYSE:PBH – Get Free Report) EVP Adel Mekhail sold 9,063 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total value of $743,166.00. Following the transaction, the executive vice president now owns 18,365 shares in the company, valued at approximately $1,505,930. This trade represents a 33.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Prestige Consumer Healthcare Stock Performance
PBH opened at $82.36 on Friday. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. The firm has a market cap of $4.07 billion, a PE ratio of 20.04, a P/E/G ratio of 2.32 and a beta of 0.47. The business has a fifty day simple moving average of $73.13 and a 200-day simple moving average of $70.18. Prestige Consumer Healthcare Inc. has a fifty-two week low of $56.61 and a fifty-two week high of $83.83.
Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The firm had revenue of $283.79 million for the quarter, compared to analysts’ expectations of $282.09 million. During the same quarter last year, the business posted $1.07 EPS. Prestige Consumer Healthcare’s revenue was down .9% on a year-over-year basis. As a group, equities analysts predict that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current fiscal year.
Institutional Investors Weigh In On Prestige Consumer Healthcare
Wall Street Analysts Forecast Growth
A number of research analysts recently issued reports on the company. DA Davidson reaffirmed a “buy” rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Jefferies Financial Group restated a “hold” rating and set a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $83.67.
View Our Latest Analysis on PBH
About Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Featured Stories
- Five stocks we like better than Prestige Consumer Healthcare
- What is a Death Cross in Stocks?
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- Using the MarketBeat Dividend Yield Calculator
- Top-Performing Non-Leveraged ETFs This Year
- Stock Sentiment Analysis: How it Works
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.